Pharma and Biotech Daily: Eisai's Leqembi Sales Disappoint, Pfizer's $1 Billion Commitment in China, AstraZeneca China Head in Custody, Lilly vs. Novo Dispute, Gene Therapy Webinar, and More

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eisai's sales of its Alzheimer's disease therapy Leqembi have disappointed analysts, leading the company to lower its fiscal 2024 guidance. The underwhelming sales are attributed to barriers such as coverage, infusion centers, and time to diagnosis. In other news, Pfizer has made a $1 billion commitment in China to boost innovation and target the Chinese market, whi...